Search Results

There are 1407949 results for: content related to: Defining disease-modifying therapies for PD—A road map for moving forward

VIEW

  1. 1 - 20
  2. 21 - 40
  3. 41 - 60
  4. 61 - 80
  5. Next >
  1. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics

    Movement Disorders

    Volume 23, Issue 15, 15 November 2008, Pages: 2194–2201, C. Warren Olanow, Robert A. Hauser, Joseph Jankovic, William Langston, Anthony Lang, Werner Poewe, Eduardo Tolosa, Fabrizio Stocchi, Eldad Melamed, Eli Eyal and Olivier Rascol

    Article first published online : 19 OCT 2008, DOI: 10.1002/mds.22218

  2. 2nd World Parkinson Congress Abstracts

    Movement Disorders

    Volume 25, Issue S3, 15 September 2010, Pages: S569–S717,

    Article first published online : 9 SEP 2010, DOI: 10.1002/mds.23386

    Corrected by:

    Erratum: Erratum

    Vol. 25, Issue 15, 2694, Article first published online: 10 NOV 2010

  3. Interpreting the results of Parkinson's disease clinical trials: Time for a change

    Movement Disorders

    Volume 26, Issue 4, March 2011, Pages: 569–577, Nick H. G. Holford and John G. Nutt

    Article first published online : 2 MAR 2011, DOI: 10.1002/mds.23555

  4. Milestones in movement disorders clinical trials: Advances and landmark studies

    Movement Disorders

    Volume 26, Issue 6, May 2011, Pages: 1003–1014, C. Warren Olanow, Kathryn B. Wunderle and Karl Kieburtz

    Article first published online : 27 MAY 2011, DOI: 10.1002/mds.23727

  5. Explaining ADAGIO: A critical review of the biological basis for the clinical effects of rasagiline

    Movement Disorders

    Volume 26, Issue 13, November 2011, Pages: 2316–2323, Peter Jenner and J. William Langston

    Article first published online : 23 SEP 2011, DOI: 10.1002/mds.23926

  6. Rationale for delayed-start study of pramipexole in Parkinson's disease: The PROUD study

    Movement Disorders

    Volume 25, Issue 11, 15 August 2010, Pages: 1627–1632, Anthony H.V. Schapira, Stefan Albrecht, Paolo Barone, Cynthia L. Comella, Michael P. McDermott, Yoshikuni Mizuno, Werner Poewe, Olivier Rascol and Kenneth Marek

    Article first published online : 11 JUN 2010, DOI: 10.1002/mds.23143

  7. Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops?

    Movement Disorders

    Volume 26, Issue 7, June 2011, Pages: 1187–1193, Carl E. Clarke, Smitaa Patel, Natalie Ives, Caroline Rick, Keith Wheatley and Richard Gray

    Article first published online : 14 APR 2011, DOI: 10.1002/mds.23519

  8. The significance of defining preclinical or prodromal Parkinson's disease

    Movement Disorders

    Volume 27, Issue 5, 15 April 2012, Pages: 666–669, C. Warren Olanow and José A. Obeso

    Article first published online : 16 APR 2012, DOI: 10.1002/mds.25019

  9. You have free access to this content
    Obstacles to the Development of a Neuroprotective Therapy for Parkinson's Disease

    Movement Disorders

    Volume 28, Issue 1, January 2013, Pages: 3–7, Fabrizio Stocchi and C. Warren Olanow

    Article first published online : 6 FEB 2013, DOI: 10.1002/mds.25337

  10. Table of Contents

    The Brown University Geriatric Psychopharmacology Update

    Volume 13, Issue 12, December 2009, Pages: 1–8,

    Article first published online : 10 NOV 2009, DOI: 10.1002/gpu.20105

  11. You have free access to this content
    Trial designs used to study neuroprotective therapy in Parkinson's disease

    Movement Disorders

    Volume 28, Issue 1, January 2013, Pages: 86–95, Anthony E. Lang, Eldad Melamed, Werner Poewe and Olivier Rascol

    Article first published online : 23 AUG 2012, DOI: 10.1002/mds.24997

  12. You have free access to this content
    Poster Presentations

    Movement Disorders

    Volume 27, Issue S1, June 2012, Pages: S1–S523,

    Article first published online : 19 JUN 2012, DOI: 10.1002/mds.25051

  13. You have free access to this content
    How should we treat a patient with early Parkinson’s disease?

    International Journal of Clinical Practice

    Volume 64, Issue 9, August 2010, Pages: 1210–1219, S. Tsouli and S. Konitsiotis

    Article first published online : 13 JUL 2010, DOI: 10.1111/j.1742-1241.2010.02371.x

  14. Abstracts of The Movement Disorder Society's Twelfth International Congress of Parkinson's Disease and Movement Disorders

    Movement Disorders

    Volume 23, Issue S1, 15 May 2008, Pages: S1–S422,

    Article first published online : 28 MAY 2008, DOI: 10.1002/mds.22133

  15. Monoamine Oxidase-B Inhibition in the Treatment of Parkinson's Disease

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 27, Issue 12P2, December 2007, Pages: 174S–185S, Dr. Hubert H. Fernandez and Dr. Jack J. Chen

    Article first published online : 6 JAN 2012, DOI: 10.1592/phco.27.12part2.174S

  16. Prospects for Neuroprotective Therapies that can Modulate Non-Dopaminergic Features in Parkinson's Disease

    Parkinson's Disease: Non-Motor and Non-Dopaminergic Features

    C. Warren Olanow, Anthony E. Lang, Pages: 455–461, 2011

    Published Online : 27 JUN 2011, DOI: 10.1002/9781444397970.ch39

  17. Milestones in Parkinson's disease therapeutics

    Movement Disorders

    Volume 26, Issue 6, May 2011, Pages: 1072–1082, Olivier Rascol, Andres Lozano, Matthew Stern and Werner Poewe

    Article first published online : 27 MAY 2011, DOI: 10.1002/mds.23714

  18. Why have we failed to achieve neuroprotection in Parkinson's disease?

    Annals of Neurology

    Volume 64, Issue S2, December 2008, Pages: S101–S110, C. Warren Olanow, Karl Kieburtz and Anthony H. V. Schapira

    Article first published online : 6 JAN 2009, DOI: 10.1002/ana.21461

  19. Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis

    Pharmaceutical Statistics

    Volume 8, Issue 3, July/September 2009, Pages: 225–238, Berend Arnold Ploeger and Nicholas H. G. Holford

    Article first published online : 24 NOV 2008, DOI: 10.1002/pst.355

  20. Prerequisites to launch neuroprotective trials in Parkinson's disease: An industry perspective

    Movement Disorders

    Volume 27, Issue 5, 15 April 2012, Pages: 651–655, Johannes R. Streffer, Igor D. Grachev, Cheryl Fitzer-Attas, Baltazar Gomez-Mancilla, Babak Boroojerdi, Juliana Bronzova, Susanne Ostrowitzki, Stephen J. Victor, Paulo Fontoura and Robert Alexander

    Article first published online : 16 APR 2012, DOI: 10.1002/mds.25017

VIEW

  1. 1 - 20
  2. 21 - 40
  3. 41 - 60
  4. 61 - 80
  5. Next >